I'll research ISRG (Intuitive Surgical) to build a well-grounded earnings preview. Let me gather recent transcripts, filings, news, and price data.The stock has fallen sharply this year — from ~$560 in January to ~$390, with a notable ~7% drop on July 14. Let me dig into the most recent quarter's call and recent news to understand the drivers.Let me find what drove the July 14 drop and any preliminary announcements or analyst expectations ahead of the print.Let me search the web for the recent news and analyst expectations.I have strong context. Let me quickly confirm the year-ago Q2 2025 baseline figures for precise YoY framing.I now have what I need. Here's the earnings preview.
Intuitive walks into this print with a rare disconnect between fundamentals and sentiment. Operationally the company just posted one of its strongest quarters in years, yet the stock has been crushed in 2026. On July 14, 2026, Intuitive Surgical shares fell 6.8% to $379.50, with shares down 33.0% year-to-date and 26.5% over the past year, against a 52-week range of $378.50 to $603.88. Shares closed at $389.01 on July 15, meaning ISRG enters the print roughly 35% below its 52-week high and sitting near multi-year sentiment lows.
Crucially, the decline has been a de-rating, not a fundamental break. The current P/E (TTM) of ~46x is well below the 5-year median P/E of ~72x — still not cheap, but a dramatic compression for a company still compounding revenue in the low-20s percent.
What the Street expects tomorrow: Analysts expect roughly $2.81 billion in revenue and $2.48 EPS, reflecting ~15% growth year-over-year, and the company has a history of beating estimates. For reference, the year-ago Q2 2025 base was $2.44B revenue (+21%) and $2.19 non-GAAP EPS, so consensus implies revenue growth decelerating to the mid-teens against a tougher comp.
Three overlapping worries have driven the sell-off, and each is a live issue into the print:
The instrument-reuse / recurring-revenue scare. Intuitive increased the lifespan of five of its six force-feedback tools, and separately plans to raise the maximum number of uses of older standard instruments to lower hospitals' costs — a move investors feared would erode the high-margin instruments & accessories (I&A) annuity. Bulls counter that this is a well-worn playbook: when Intuitive launched its Extended Use Program in 2020, it modeled a 7% drop in revenue per procedure but the actual hit was just 2% before revenue growth resumed, and premium force-feedback instruments should offset the cheaper core tools.
da Vinci 5 margin dilution + tariffs. Headwinds include lower-than-expected profit margins on the da Vinci 5 (strong acceptance but lower margins than its predecessor) plus rising costs from high tariffs.
Pre-earnings de-risking and target cuts. The July 14 drop was tied to a mix of pre-earnings caution and a fresh analyst price-target cut highlighting valuation and competitive concerns, not a new business setback. Notably, several analysts downgraded after Q1 earnings — including Deutsche Bank, Bank of America, JPMorgan and HSBC — while Goldman Sachs' David Roman raised his target to $558. The bull/bear split is wide: 16 analysts have offered price targets in the last 6 months with a median of $580.
The bottom line on positioning: expectations have been reset lower and sentiment is washed out, which raises the odds that an in-line-to-better print (Intuitive's historical norm) is received well — but it also means any crack in the recurring-revenue or margin narrative gets punished hard.
This is the metric the whole thesis hangs on. The company entered 2026 guiding da Vinci procedure growth of 13%–15%, down from 18% in 2025, but Q1 came in above range at 17%. On the Q1 call, management raised full-year da Vinci procedure growth to 13.5%–15.5%. Watch for: - Whether Q2 procedure growth holds in the mid-to-high teens (it was +17% total / +16% da Vinci in Q1, vs. +17% da Vinci a year ago). - Any further raise (or a "de-risking" hold) to the full-year range — the single biggest potential share catalyst. - U.S. general surgery momentum: cholecystectomy + appendectomy grew 31% combined in Q1, aided by after-hours/weekend cases. Appendectomy (~300k U.S. procedures/yr) is an emerging TAM management just began calling out. - Benign gynecology, where targeted clinical investment drove +19% in non-hysterectomy benign procedures. - Bariatrics, which fell ~10% in Q1 on GLP-1 headwinds — watch whether the drag is stabilizing.
da Vinci I&A/procedure was ~$1,880 in Q1 (up from ~$1,780). This is the number bears are dissecting for early evidence of instrument-life extension eating into the annuity. Positive offsets to watch: force-feedback instrument ramp (supply was expanding through 2026), higher SP/dV5 mix, and the SP stapler moving to broad launch.
Q1 non-GAAP gross margin was 67.8% (up YoY). Management guides full-year to 67.5%–68.5%, embedding ~100 bps of tariff drag plus higher freight and semiconductor memory costs. Key positive from Q1: da Vinci 5 contribution margin reached parity with Xi, and Ion is near corporate-average contribution margin. Watch whether tariff/oil/memory pressure builds sequentially as flagged (impact rolls through inventory over the year).
The soft spot. Management has flagged China (weak tenders, domestic competition, pricing pressure — no policy clarity expected until 2027) and Japan (weak recent capital, though new June 2026 reimbursements for 7 procedures + volume incentives are modest positives). Europe capital was a Q1 bright spot (UK NHS year-end budget flush). OUS is now 38% of da Vinci volume, so any incremental China/Japan deterioration matters.
Management remains cautious on ACA enhanced-premium subsidy expiration and Medicaid coverage changes as potential procedure headwinds. No material impact seen in Q1, but any commentary on early Q2 trends will be scrutinized given the elective-procedure exposure.
| Bull case | Bear case | |
|---|---|---|
| Procedures | +17% in Q1 above guide; another beat/raise likely | Tough comps, ACA/Medicaid + bariatric drag could slow to 13% |
| Recurring rev | Instrument-life history shows minimal net hit; premium mix offsets | Reuse extensions structurally lower I&A/procedure |
| Margins | dV5 at Xi parity; fixed-cost leverage on 20%+ growth | Tariffs, memory/oil, dV5/Ion mix, trade-ins pressure GM |
| Valuation | ~46x P/E vs ~72x historical; GF Value implies deep discount | Still ~46–50x on decelerating growth; competition rising |
| Intl | UK/Europe reimbursement, Japan policy, SP in Korea | China/Japan capital and pricing remain stuck |
Given the washed-out setup, the reaction likely hinges on (1) the full-year procedure growth guide (raise = relief rally; hold/trim = renewed pressure), and (2) the I&A/procedure trajectory as the referendum on the recurring-revenue fear. A clean beat with a raised procedure outlook against a stock down 33% YTD sets up an asymmetric bounce; conversely, any confirmation that instrument-reuse is denting the annuity — or that tariffs/mix are compressing gross margin below the guide — would validate the bears at a still-premium multiple.
Note: Figures cited from prior quarters (Q1 2026 and Q2 2025) are drawn from Intuitive's own earnings calls; consensus, price and analyst data are from public news sources dated July 2026. This is research context, not investment advice.